butamirate | Codelac Neo syrup 1.5 mg / ml, 100 ml

Latin name

CodelacВ® Neo

Release form

Syrup

Packing

Bottle 100 ml

Pharmacological action

Codelac Neo - antitussive, expectorant, bronchodilating, anti-inflammatory.

pharmacodynamics

antitussive non-opioid agent, It has a direct effect on the cough center. Butamyrate citrate is neither chemically nor pharmacologically related to opium alkaloids.

It has an antitussive, expectorant, moderate bronchodilating and anti-inflammatory effect, improves spirometry (reduces airway resistance) and blood oxygenation.

Pharmacokinetics

Drops for oral administration,

syrup Absorption. After oral administration, the drug is rapidly and completely absorbed from the digestive tract. After taking 150 mg of Cmax butamirate, the main metabolite (2-phenylbutyric acid) in the blood plasma is reached after about 1.5 hours and is 6.4 μg / ml.

Distribution and metabolism. The hydrolysis of butamirate, initially to 2-phenylbutyric acid and diethylaminoethoxyethanol, begins in the blood. These metabolites also have antitussive activity, and, Like butamirate, to a large extent (about 95%) they bind to plasma proteins, which leads to their long-term T1 / 2. 2-phenylbutyric acid is partially metabolized by hydroxylation.

With repeated use of the drug, cumulation is not observed.

Withdrawal. T1 / 2 is 6 hours. All three metabolites are excreted mainly in the urine. Moreover, 2-phenylbutyric acid is mainly excreted in the form bound to glucuronic acid.

Indications

Dry cough of any etiology (for colds, flu, whooping cough and other conditions) suppression of cough in the preoperative and postoperative period, during surgical interventions and bronchoscopy.

Contraindications

hypersensitivity to the components of the drug

pregnancy (I trimester)

breastfeeding period

intolerance to fructose

children under 3 years of age (syrup).

Use during pregnancy and lactation

There is no data on the safety of the drug during pregnancy and its passage through the placental barrier.

The use of the drug in the first trimester of pregnancy is contraindicated.

In the second and third trimesters of pregnancy, the use of the drug is possible taking into account the ratio of benefits for the mother and potential risk to the fetus.

The penetration of the drug into breast milk has not been studied, therefore, the use of the drug during breastfeeding is not recommended.

Composition of

5 ml of syrup contains:

Active ingredient:

butyrate citrate (in terms of 100% substance) 7.5 mg

Excipients:

sorbitol (Neosorb 70/70, sorbitol syrup) - 2025 mg serlkp ) - 1450 mg

ethanol 95% (ethanol 95%) - 12.69 mg

sodium saccharin - 3 mg

benzoic acid - 5.75 mg

vanillin - 3 mg

sodium hydroxide solution 30% - 1.55 mg

purified water - up to 5 ml

Dosage and administration

For children from 3 to 6 years old - 5 ml 3 times a day from 6 to 12 years old - 10 ml 3 times a day 12 years and older - 15 ml 3 times a day for adults - 15 ml 4 times in a day.

When taking the drug, use a measuring device.

Side effects

From the side of the central nervous system: dizziness, which occurs when you stop taking the drug or reduce the dose of drowsiness.

From the digestive system: nausea, vomiting, diarrhea.

From the skin: exanthema.

Allergic reactions: skin rash, itching.

Overdose

Symptoms: nausea, vomiting, drowsiness, diarrhea, abdominal pain, dizziness, irritability, decreased BP, impaired movement coordination.

Treatment: appointment of activated charcoal, gastric lavage, salt laxatives, symptomatic therapy (as indicated).

Storage conditions

At a temperature not exceeding 25 РC.

Expiration

2 Year

Deystvuyuschee substances

butamirate

Dosage form

Dosage form

solution for oral administration

Pharmstandard-Leksredstva, Russia